Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
Abstract Background ‘Clinically important deterioration’ (CID) is a composite endpoint measuring worsening of the key clinical features of chronic obstructive pulmonary disease (COPD), namely lung function, patient-reported outcomes, and exacerbations. ACLIFORM and AUGMENT were two 24-week, randomiz...
Main Authors: | Dave Singh, Anthony D. D’Urzo, Ferran Chuecos, Anna Muñoz, Esther Garcia Gil |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12931-017-0583-0 |
Similar Items
-
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01) -
Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD
by: Chen R, et al.
Published: (2020-01-01) -
Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment
by: Shih-Lung Cheng
Published: (2021-06-01) -
An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
by: Singh D, et al.
Published: (2019-12-01) -
Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
by: Anthony D’Urzo, et al.
Published: (2019-03-01)